apceth Biopharma appoints Dusan Kosijer as Chief Financial Officer

apceth Biopharma GmbH (www.apceth.com), a cell therapy company with a proprietary portfolio of genetically modified mesenchymal stem cell therapeutics for the treatment of inflammatory diseases and cancer, and a successful Contract Development and Manufacturing Organisation (CDMO) for cell and gene therapy products, announced today the appointment of Mr Dusan Kosijer as new Chief Financial Officer, effective immediately. Download Press Release ENG (PDF) Please note: today apceth Biopharma focuses solely on the CDMO business

bluebird bio and apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer and apceth Biopharma GmbH (www.apceth.com), the global innovator and leader in the development of engineered mesenchymal stem cell (MSC) therapeutics and a successful and established contract development and manufacturing organization in the field of cell and gene therapy, announced today that they have entered into a strategic manufacturing agreement providing for the future European commercial production of bluebird bio’s Lenti-D™ product candidate for cerebral adrenoleukodystropy and its LentiGlobin™ product candidate for transfusion-dependent β-thalassemia. Downolad Press Release ENG, DE (PDF) Please note: today apceth Biopharma focuses solely on the CDMO business